Don't Miss


Nonalcoholic Steatohepatitis: KOL Insight Which NASH products are most likely to succeed as the new treatment paradigm develops?
At this stage of the game, it's unclear if one drug is going dominate the market. With significant clinical unmet need, plenty of room exists for diverse approaches. Nonalcoholic Steatohepatitis: KOL Insight reveals critical US and European KOL views on pipeline products, biomarkers, combination therapy, prescribing decision factors and what they see as emerging clinical benefits and challenges. Learn more.

GlaxoSmithKline reaches deal to add meningitis B vaccine Bexsero to UK childhood vaccination programme